| Name | Title | Contact Details |
|---|
Southern Regional Medical Center (SRMC) is a 331-bed hospital serving Riverdale, Georgia, and the surrounding communities. The hospital is owned by Prime Healthcare, an award winning health system that owns nearly 50 hospitals in 14 states.
PharmaNet is an international drug development company employing about 1,500 professionals worldwide.
We are a non-profit, Michigan-based company and a subsidiary of the Henry Ford Health System, one of the nation`s leading health care systems. We provide health plans for everyone -- individuals and companies of all sizes. Since 1960, we`ve partnered with leading doctors, hospitals, employers and community organizations to enhance the lives of those we touch. We offer six distinct health insurance lines: • Group Insured Commercial • Individual • Medicare • Medicaid • Self-Funded • Network Leasing HAP also provides: • Award-winning wellness programs • Community outreach • Digital health tools • Disease management services • Personalized customer service
Who We Serve We provide services to the loved ones of all people enrolled in the Capital Hospice program - as well as to the larger community - who are coping with grief.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.